Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Cryopreservation of human colorectal carcinomas prior to xenografting

Authors: Michael Linnebacher, Claudia Maletzki, Christiane Ostwald, Ulrike Klier, Mathias Krohn, Ernst Klar, Friedrich Prall

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Molecular heterogeneity of colorectal carcinoma (CRC) is well recognized, forming the rationale for molecular tests required before administration of some of the novel targeted therapies that now are rapidly entering the clinics. For clinical research at least, but possibly even for future individualized tumor treatment on a routine basis, propagation of patients' CRC tissue may be highly desirable for detailed molecular, biochemical or functional analyses. However, complex logistics requiring close liaison between surgery, pathology, laboratory researchers and animal care facilities are a major drawback in this. We here describe and evaluate a very simple cryopreservation procedure for colorectal carcinoma tissue prior to xenografting that will considerably reduce this logistic complexity.

Methods

Fourty-eight CRC collected ad hoc were xenografted subcutaneously into immunodeficient mice either fresh from surgery (N = 23) or after cryopreservation (N = 31; up to 643 days).

Results

Take rates after cryopreservation were satisfactory (71%) though somewhat lower than with tumor tissues fresh from surgery (74%), but this difference was not statistically significant. Re-transplantation of cryopreserved established xenografts (N = 11) was always successful. Of note, in this series, all of the major molecular types of CRC were xenografted successfully, even after cryopreservation.

Conclusions

Our procedure facilitates collection, long-time storage and propagation of clinical CRC specimens (even from different centres) for (pre)clinical studies of novel therapies or for basic research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jass JR: Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol. 2007, 16: 7-9. 10.1016/j.suronc.2007.10.039.CrossRef Jass JR: Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol. 2007, 16: 7-9. 10.1016/j.suronc.2007.10.039.CrossRef
2.
go back to reference Ostwald C, Linnebacher M, Weirich V, Prall F: Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol. 2009, 35: 321-7.PubMed Ostwald C, Linnebacher M, Weirich V, Prall F: Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol. 2009, 35: 321-7.PubMed
3.
go back to reference Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science. 2007, 318: 1108-13. 10.1126/science.1145720.CrossRefPubMed Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science. 2007, 318: 1108-13. 10.1126/science.1145720.CrossRefPubMed
5.
go back to reference Freeman DJ, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008, 7 (3): 184-90. 10.3816/CCC.2008.n.024.CrossRefPubMed Freeman DJ, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008, 7 (3): 184-90. 10.3816/CCC.2008.n.024.CrossRefPubMed
6.
go back to reference Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1626-34. 10.1200/JCO.2007.14.7116.CrossRefPubMed Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 1626-34. 10.1200/JCO.2007.14.7116.CrossRefPubMed
7.
go back to reference Kerbel RS: Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003, 2: 134-9. Kerbel RS: Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003, 2: 134-9.
8.
go back to reference Sausville EA, Burger AM: Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66: 3351-4. 10.1158/0008-5472.CAN-05-3627.CrossRefPubMed Sausville EA, Burger AM: Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66: 3351-4. 10.1158/0008-5472.CAN-05-3627.CrossRefPubMed
9.
go back to reference Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003, 9: 4227-39.PubMed Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003, 9: 4227-39.PubMed
10.
go back to reference Fielding LP, Arsenault PA, Chapuis PH, et al: Clinocpatholgoical staging for colorectal cancer: an International Documentation System (IDS) and an Interantional Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol. 1991, 6: 325-44. 10.1111/j.1440-1746.1991.tb00867.x.CrossRefPubMed Fielding LP, Arsenault PA, Chapuis PH, et al: Clinocpatholgoical staging for colorectal cancer: an International Documentation System (IDS) and an Interantional Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol. 1991, 6: 325-44. 10.1111/j.1440-1746.1991.tb00867.x.CrossRefPubMed
11.
go back to reference Matsuda H, Seo Y, Kakizaki E, Kozawa S, Muraoka E, Yukawa N: Identification of DNA of human origin based on amplification of human-specific mitochondrial cytochrome b region. Forensic Sci Int. 2005, 152: 109-14. 10.1016/j.forsciint.2004.07.019.CrossRefPubMed Matsuda H, Seo Y, Kakizaki E, Kozawa S, Muraoka E, Yukawa N: Identification of DNA of human origin based on amplification of human-specific mitochondrial cytochrome b region. Forensic Sci Int. 2005, 152: 109-14. 10.1016/j.forsciint.2004.07.019.CrossRefPubMed
12.
go back to reference Bocsi J, Zalatnai A: Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. J Cancer Res Clin Oncol. 1999, 125: 9-19. 10.1007/s004320050236.CrossRefPubMed Bocsi J, Zalatnai A: Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. J Cancer Res Clin Oncol. 1999, 125: 9-19. 10.1007/s004320050236.CrossRefPubMed
13.
go back to reference Cui JH, Krüger U, Vogel I, et al: Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology. 1998, 45: 2087-96.PubMed Cui JH, Krüger U, Vogel I, et al: Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology. 1998, 45: 2087-96.PubMed
14.
go back to reference Sorio C, Bonora A, Orlandini S, et al: Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch. 2001, 438: 154-8. 10.1007/s004280000343.CrossRefPubMed Sorio C, Bonora A, Orlandini S, et al: Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch. 2001, 438: 154-8. 10.1007/s004280000343.CrossRefPubMed
15.
go back to reference Fujii E, Suzuki M, Matsubara K, et al: Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol Int. 2008, 58: 559-67. 10.1111/j.1440-1827.2008.02271.x.CrossRefPubMed Fujii E, Suzuki M, Matsubara K, et al: Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol Int. 2008, 58: 559-67. 10.1111/j.1440-1827.2008.02271.x.CrossRefPubMed
16.
go back to reference Bellett AJ, Younghusband HB: Spontaneous, mutagen-induced and adenovirus-induced anchorage independent tumorigenic variants of mouse cells. J Cell Physiol. 1979, 101: 33-47. 10.1002/jcp.1041010106.CrossRefPubMed Bellett AJ, Younghusband HB: Spontaneous, mutagen-induced and adenovirus-induced anchorage independent tumorigenic variants of mouse cells. J Cell Physiol. 1979, 101: 33-47. 10.1002/jcp.1041010106.CrossRefPubMed
17.
go back to reference Reyes G, Villanueva A, García C, et al: Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 1996, 56: 5713-9.PubMed Reyes G, Villanueva A, García C, et al: Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 1996, 56: 5713-9.PubMed
Metadata
Title
Cryopreservation of human colorectal carcinomas prior to xenografting
Authors
Michael Linnebacher
Claudia Maletzki
Christiane Ostwald
Ulrike Klier
Mathias Krohn
Ernst Klar
Friedrich Prall
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-362

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine